IgG antibody
Goat anti Monkey IgG antibody (AAI41) used for the evaluation of IgG responses in cynomolgus macaques following immunization by ELISA.
Image caption:
Serum and mucosally-detected anti-gp140 antibody titres after intravaginal immunisation followed by intramuscular immunisation (Group A). The intravaginal immunisation cycles, each consisting of 9× 100 μg gp140, are shown as broad stippled areas and intramuscular immunisation is indicated by a thin stippled line. For each animal, E53, E54, E55 and E56 results are shown for serum and cervical and vaginal fluids, with IgG indicated by filled symbols and IgA indicated by open symbols. Limits of detection for serum antibodies were titres of 100 and 10 for IgG and IgA respectively.
From: Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, Cole T, Mahmoud AN, Hall J, Giles E, Voss G, Page M, Almond N, Shattock RJ. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.
Vaccine. 2011 Feb 4;29(7):1421-30.
Goat anti Monkey IgG antibody (AAI42) used for the evaluation of IgG responses in cynomolgus macaques following immunization by ELISA.
Image caption:
Serum and mucosally-detected anti-gp140 antibody titres after a single intramuscular immunisation followed by intravaginal immunisation (Group B) or a single intramuscular immunisation alone (Group D). The intramuscular immunisation is indicated by a thin stippled line and the intravaginal immunisation cycle, consisting of 9× 100 μg gp140, is shown as a broad stippled area. For each animal, E49, E50, E51, E52 (Group B) and E107 and E108 (Group D) results are shown for serum and cervical and vaginal fluids, with IgG indicated by filled symbols and IgA indicated by open symbols. Limits of detection for serum antibodies were titres of 100 and 10 for IgG and IgA respectively.
From: Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, Cole T, Mahmoud AN, Hall J, Giles E, Voss G, Page M, Almond N, Shattock RJ. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.
Vaccine. 2011 Feb 4;29(7):1421-30.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Goat anti Monkey IgG antibody (AAI42) used for the evaluation of IgG responses in cynomolgus macaques following immunization by ELISA.
Image caption:
Serum and mucosally-detected anti-gp140 antibody titres after three intramuscular immunisations followed by intravaginal immunisation (Group C). The intramuscular immunisations are indicated by thin stippled lines and the intravaginal immunisation cycle, consisting of 9× 100 μg gp140, is shown as a broad stippled area. For each animal, E57, E58, E59 and E60 results are shown for serum and cervical and vaginal fluids, with IgG indicated by filled symbols and IgA indicated by open symbols. Limits of detection for serum antibodies were titres of 100 and 10 for IgG and IgA respectively.
From: Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, Cole T, Mahmoud AN, Hall J, Giles E, Voss G, Page M, Almond N, Shattock RJ. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.
Vaccine. 2011 Feb 4;29(7):1421-30.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Goat anti Monkey IgG antibody (AAI42) used for the evaluation of IgG responses in cynomolgus macaques following immunization by ELISA.
Image caption:
Comparison of anti-gp140 specific antibodies and total immunoglobulins in vaginal and cervical secretions. Animals were immunised either once or three times by intramuscular immunisation with gp-140 in AS01 adjuvant followed by a cycle of 9 intravaginal immunisations with gp140 in Carbopol gel (Groups B and C) (a) The median titres of IgG and IgA antibodies were significantly different at the P = 0.006 (**) level for IgG but were not significantly different (ns) for IgA P = 0.097 (Mann–Whitney ranked sum test). (b) Total IgG concentrations were significantly higher in cervical secretions, P = 0.001 (**) (Mann–Whitney ranked sum test). (c) Total IgA concentrations in fluids from the two sites were not significantly different, P = 0.22. Group mean (- - -) and median (—) titres are shown with box plots.
From: Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, Cole T, Mahmoud AN, Hall J, Giles E, Voss G, Page M, Almond N, Shattock RJ. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.
Vaccine. 2011 Feb 4;29(7):1421-30.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Goat anti Monkey IgG antibody (AAI42) used for the evaluation of IgG responses in cynomolgus macaques following immunization by ELISA.
Image caption:
Correlation between virus neutralising activity and serum binding antibody titres. Neutralising activity was measured in sequential serum samples against tier 1 clade C HIV-1 MW963.26 pseudovirus and compared to serum IgG and IgA gp140 binding antibody titres from macaques immunised with gp140 by intravaginal-systemic (Group A) and systemic-intravaginal (Groups B and C) protocols.
From: Cranage MP, Fraser CA, Cope A, McKay PF, Seaman MS, Cole T, Mahmoud AN, Hall J, Giles E, Voss G, Page M, Almond N, Shattock RJ. Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.
Vaccine. 2011 Feb 4;29(7):1421-30.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Detection of anti SIV antibodies in serum by Goat anti Monkey IgG antibody (AAI42) in an ELISA.
Image caption:
Comparison of longitudinal anti-Gag p27 IgG responses in fully and partially protected vaccinates.
Anti-SIV p27 responses are shown prior to and post wild-type SIVmac239 challenge. None of the protected macaques (E65, E70, E73, E75, E76, E77) displayed a boosted antibody response to SIV Gag p27 antigen. All partially protected macaques (E61, E63, E66, E67, E68, E71) exhibited a boosted anti-SIV p27 response.
From: Berry N, Manoussaka M, Ham C, Ferguson D, Tudor H, Mattiuzzo G, et al. (2016)
Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine.
PLoS Pathog 12(12): e1006083.
This image is from an open access article distributed under the terms of the Creative Commons Attribution License.
Horseradish peroxidase conjugated Goat anti Monkey IgG (H/L) antibody (AAI42P) used to evaluate antigen specific IgG responses in Rhesus macaque by ELISA.
Image caption:
Specific anti-gp120 HIV-1CM244 IgG and IgA levels elicited during vaccination with ALVAC/AIDSVAX. (a) Immunization and sampling schedule. (b–e) Explant culture supernatants were harvested during the 15 days of culture of tissues obtained 2 weeks after each vaccination ((b,c) cervical (open symbols) and vaginal (closed symbols); (d,e) rectal (open symbols) and sigmoidal (closed symbols)). The data shown are the sum of the Ab concentrations measured in triplicate at harvest days 3, 7, 11, and 15 during the culture period for tissue explants from each macaque. (f,g) Vaginal and (h,i) rectal secretions were extracted from Weck-Cel sponges collected from each animal 2 weeks after each vaccination, and Ab concentrations were measured in triplicate. (j,k) Serum was obtained for each animal from blood collected 1 and 2 weeks after each vaccination and Ab concentrations were quantified in triplicate. Means are shown with lines. Statistical significance: * p ≤0.05, ** p ≤0.01, *** p ≤0.001, **** p ≤0.0001.
From: Herrera, C.; Veazey, R.; Lemke, M.M.; Arnold, K.; Kim, J.H.; Shattock, R.J.
Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates.
Vaccines 2022, 10, 187.
doi:10.3390/vaccines10020187.
This image is from an open access article distributed under terms of a Creative Commons Attribution License.
Filter by Application:
E ResetGoat anti Monkey IgG (H/L)
- Product Type
- Polyclonal Antibody
- Isotype
- Polyclonal IgG
- Specificity
- IgG
- Region
- (H/L)
Antibody Quality and Performance Guarantee
| Goat anti Monkey IgG (H/L) antibody recognizes monkey IgG (heavy and light chains). Goat anti Monkey IgG (H/L) antibody has been shown to react specifically with monkey IgG heavy chains and with light chains common to other monkey immunoglobulins by immunoelectrophoresis and ELISA. Reaction to human was also detected. Goat anti Monkey IgG (H/L) antibody may cross react with IgG from other species. |
- Target Species
- Monkey
- Species Cross-Reactivity
-
Target Species Cross Reactivity Human African green monkey Cynomolgus monkey Baboon Chimpanzee Rhesus Monkey - N.B. Antibody reactivity and working conditions may vary between species.
- Product Form
- Purified IgG - liquid
- Antiserum Preparation
- Antisera to monkey IgG were raised by repeated immunisation of goat with highly purified antigen. Purified IgG prepared by affinity chromatography.
- Buffer Solution
- Phosphate buffered saline
- Preservative Stabilisers
- 0.09% Sodium Azide (NaN3)
- Immunogen
- Purified monkey IgG.
- Approx. Protein Concentrations
- IgG concentration 1.0 mg/ml
- Regulatory
- For research purposes only
- Guarantee
- 12 months from date of despatch
Store at +4oC. DO NOT FREEZE.
This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.
This product should be stored undiluted. Should this product contain a precipitate we recommend microcentrifugation before use.
This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit the antibody protocols page.
| Application Name | Verified | Min Dilution | Max Dilution |
|---|---|---|---|
| ELISA |  |
1/100 | 1/1000 |
| Immunodiffusion | |
Where this antibody has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the antibody for use in their own system using the appropriate negative/positive controls.
| Description | Product Code | Applications | Pack Size | List Price | Your Price | Quantity | |
|---|---|---|---|---|---|---|---|
| Rabbit anti Goat IgG (Fc):FITC | STAR122F | F | 1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Rabbit anti Goat IgG (Fc):FITC | ||||||
| Rabbit anti Goat IgG (Fc):HRP | STAR122P | C E WB | 1 mg |
|
Log in | ||
| List Price | Your Price | ||||||
|
|
Log in | ||||||
| Description | Rabbit anti Goat IgG (Fc):HRP | ||||||
References for IgG antibody
-
Lemere, C.A. et al. (2004) Alzheimer's disease abeta vaccine reduces central nervous system abeta levels in a non-human primate, the Caribbean vervet.
Am J Pathol. 165: 283-97. -
Turbant, S. et al. (2009) Cynomolgus macaques immunized with two HIV-1 Tat stabilized proteins raise strong and long-lasting immune responses with a pattern of Th1/Th2 response differing from that in mice.
Vaccine. 27: 5349-56. -
Goodrich, R.P. et al. (2009) Evaluation of potential immune response and in vivo survival of riboflavin-ultraviolet light-treated red blood cells in baboons.
Transfusion. 49: 64-74. -
Tillou, X. et al. (2010) Recombinant human C1-inhibitor prevents acute antibody-mediated rejection in alloimmunized baboons.
Kidney Int. 78: 152-9. -
Cranage, M.P. et al. (2011) Antibody responses after intravaginal immunisation with trimeric HIV-1 CN54 clade C gp140 in Carbopol gel are augmented by systemic priming or boosting with an adjuvanted formulation.
Vaccine. 29: 1421-30. -
Angin, M. et al. (2012) Gene transfer of human CD40Ig does not prevent rejection in a non-human primate kidney allotransplantation model.
Transpl Immunol. 27: 139-45. -
Aliesky, H. et al. (2013) Thyroid autoantibodies are rare in nonhuman great apes and hypothyroidism cannot be attributed to thyroid autoimmunity.
Endocrinology. 154 (12): 4896-907. -
Mayer, A.E. et al. (2014) The neutralizing capacity of antibodies elicited by parainfluenza virus infection of African Green Monkeys is dependent on complement.
Virology. 460-461: 23-33.
View The Latest Product References
-
Warfel, J.M. et al. (2014) Maternal and neonatal vaccination protects newborn baboons from pertussis infection.
J Infect Dis. 210 (4): 604-10. -
Dereuddre-Bosquet, N. et al. (2015) HIV specific responses induced in nonhuman primates with ANRS HIV-Lipo-5 vaccine combined with rMVA-HIV prime or boost immunizations.
Vaccine. 33 (20): 2354-9. -
Aron Badin, R. et al. (2016) Cell Therapy for Parkinson's Disease: A Translational Approach to Assess the Role of Local and Systemic Immunosuppression.
Am J Transplant. 16 (7): 2016-29. -
Berry, N. et al. (2016) Role of Occult and Post-acute Phase Replication in Protective Immunity Induced with a Novel Live Attenuated SIV Vaccine.
PLoS Pathog. 12 (12): e1006083. -
Pejoski, D. et al. (2016) Identification of Vaccine-Altered Circulating B Cell Phenotypes Using Mass Cytometry and a Two-Step Clustering Analysis.
J Immunol. 196 (11): 4814-31. -
Herrera, C. et al. (2022) Ex Vivo. Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates
Vaccines. 10 (2): 187.
- RRID
- AB_322528
AAI42
150792
157043
160904
166794
If you cannot find the batch/lot you are looking for please contact our technical support team for assistance.
View more products with IGG specificity
Please Note: All Products are "FOR RESEARCH PURPOSES ONLY"
View all Anti-Monkey ProductsAlways be the first to know.
When we launch new products and resources to help you achieve more in the lab.
Yes, sign me up